Traders should monitor progress in the radiopharmaceutical pipeline, especially early clinical data readouts. The 50/50 structure enhances Regeneron's long-term revenue potential compared to traditional licensing deals, but also increases R&D spend. Any opt-out by Telix on co-funding would shift the risk to Regeneron but reduce future profit share.
REGN drugs
REGN drug pipeline →- ● Otarmeni 3/10 Approved (accelerated approval) · BLA filing 2026
- ▲ Cemdisiran 6/10 Filed/PDUFA (Phase 3 NIMBLE complete; NDA under FDA Priority Review)
- ▲ Dupixent 4/10 Approved (marketed since 2017; additional Phase 3 trials ongoing for label expansion)
- ● Evkeeza 4/10 Approved
- ● EYLEA HD 4/10 Approved
- 12 more · All REGN drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 13 $745.61entry
- T+1 · 7mo ago +1.29%α +0.08% · $755.25
- T+5 · 7mo ago +0.49%α −2.81% · $749.26
- T+20 · 6mo ago −4.81%α −12.54% · $709.73
- T+60 · 4mo ago −9.30%α −18.28% · $676.23
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Regeneron and Telix announced a collaboration to co-develop and co-commercialize next-generation radiopharmaceutical therapies, with Regeneron paying $40 million upfront for access to four initial programs. The 50/50 cost and profit-sharing model marks Regeneron's strategic entry into radiopharmaceuticals, combining its antibody expertise with Telix’s radiopharmaceutical infrastructure.
Key Financial Metrics
Key Facts
- Regeneron pays Telix $40 million upfront for four initial radiopharmaceutical programs.
- Partnership operates under a 50/50 cost and profit-sharing model, with co-development and co-commercialization rights.
- Telix retains option to opt-out of co-funding and instead receive up to $535 million per program in milestones plus low double-digit royalties.
- Regeneron gains option to expand the collaboration to four additional programs with further upfront payments.
- Joint development of radio-diagnostics to support patient selection and treatment monitoring.
Financial Impact
$40 million upfront payment; potential future milestone payments up to $2.1 billion aggregate; 50% shared commercialization costs and profits.
Risk Factors
- Clinical failure risk in early-stage radiopharmaceutical programs.
- Potential for Telix to opt-out of co-funding, increasing Regeneron's financial burden.
- Regulatory delays in novel radiopharmaceutical approvals.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3272314 |
Track record
53 reports on REGN
11 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +31.76% at T+20 after the Oct 6, 2026 report. 16 of 20 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $951.23 Now $952.40 +0.12% settles Dec 16
- Nov 16, 2026today 144 Neutral 2/10 Entry $948.00 Now $952.40 +0.46% settles Dec 16
- Nov 12, 20264d ago Press Release Bullish 5/10 Entry $955.47 Now $952.40 −0.32% settles Dec 14
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
- Nov 5, 202611d ago Insider Cluster Neutral 3/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
- Nov 4, 202612d ago 144 Neutral 1/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers